https://www.selleckchem.com/pr....oducts/chir-99021-ct
Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and echocardiographic parameters in HFrEF outpatients previously treated with optimized therapy. Forty-nine HFrEF outpatients were retrospectively included in the study. We collected data from transthoracic echocardiography and clinical assessment at baseline and after 3±1 and 12±1months of treatment with SV. Results were also stratified by sex to analy
Like
Comment
Share
